Susan Shore Device 2025. Dr. Susan Shore named Merle Lawrence Collegiate Professor of Otolaryngology Research This is significant because its goal is to disrupt the synchrony in the dorsal cochlear nucleus, a key area in the auditory brainstem believed to drive tinnitus. Up to 15% of adults in the United States have tinnitus, where nearly 40% of sufferers have the condition chronically and
Interview with Dr. Susan Shore, PT, Ph.D, Author of the Cardiopulmonary Rehabilitation app YouTube from www.youtube.com
Shore created provides sound stimulation to the ear combined with mild electrical stimulation of the neck or jaw. its use in other clinical trials at U-M and the new Phase I trials that started in March 2025
Interview with Dr. Susan Shore, PT, Ph.D, Author of the Cardiopulmonary Rehabilitation app YouTube
The breakthrough device — based on 20 years of Shore's research and $14 million in funding — is "nearly market ready," according to Auricle Inc CEO and Co-Founder, Jon Pearson Also referred to as the Susan Shore device, this device is expected to be submitted for FDA approval for use in 2024, though it can be expected to take around 12-18 months for approval, if the FDA does award it an approval for use as a tinnitus treatment What's in development? What's promising? What's available soon? Current topics include CS0022 (BMS-191011), FX-322, OTO-313, Susan Shore device, NHPN-1010, Lenire, GW-201 (GW-TT1), Jianxin Bao, tetrandrine, OtoBand, Sulodexide, 6B-001, and more
Dra. Susan Shore Device Auricle and possible improvements in tinnitus Tinnitus Forums. This is significant because its goal is to disrupt the synchrony in the dorsal cochlear nucleus, a key area in the auditory brainstem believed to drive tinnitus. Up to 15% of adults in the United States have tinnitus, where nearly 40% of sufferers have the condition chronically and
Noxacusis (Pain Hyperacusis) Explained Mechanisms, Treatments. Can Susan Shore's Device Help. its use in other clinical trials at U-M and the new Phase I trials that started in March 2025 What's in development? What's promising? What's available soon? Current topics include CS0022 (BMS-191011), FX-322, OTO-313, Susan Shore device, NHPN-1010, Lenire, GW-201 (GW-TT1), Jianxin Bao, tetrandrine, OtoBand, Sulodexide, 6B-001, and more